Gamma Biosciences Announces Additions to Its Senior Management Team
Gamma Biosciences appoints Gabe Longoria as its Gabe Longoria.
FREMONT, CA: Gamma Biosciences, a global life sciences firm serving the advanced therapy market, announces two additions to the senior management team of Astrea Bioseparations. Gabe Longoria will come to Astrea as Chief Commercial Officer, effective April 5. Gabe follows Marc Hummersone, who joined Astrea as Senior Director of Research and Development in January of this year.
Gabe brings about 25 years of commercial experience in life sciences and biotherapeutics with an exciting track record of driving commercial growth. Similarly, Marc joins the firm with over two decades of expertise in the life sciences sector, leading technology teams in both large and small enterprises. These additions are a needed step as the company continues to improve its technical and commercial potentials, reinforcing Astrea's position as a market pioneer.
Mr Longoria previously served as Global Head of Commercial at Horizon Discovery, heading customer-facing operations and strategy. Before Horizon, he held many senior roles focused on commercial acceleration and sales success at Danaher Corporation firms Molecular Devices, Leica Microsystems and Genetix, and Ventana Medical Systems the Roche Group. Dr Hummersone, who has a PhD in Chemistry, joins Astrea from Cytiva and was previously Chief Scientific Officer of Puridify. He brings vast experience in drug discovery and development and biopharmaceutical manufacturing.
Gamma Biosciences acquires Astrea in late 2019 and has invested significantly o grow the business in its core and adjacent markets, both organically and inorganically. In 2020, Gamma added Essential Life Solutions and Nanopareil to its bioseparations, providing and continues to look for opportunities to widen its growing presence in downstream processing.
Gamma Biosciences is a life sciences company that develops and commercializes products and services to help advanced biologics manufacturing. The enterprise is committed to innovating the science and art of bioprocessing by offering market-ready innovation that enables customers to safely and efficiently bring therapies to patients.